ViiV Healthcare, July 2023 Join in the discussion with Dr Nneka Nwokolo on health issues faced by women living with HIV. Dr Nwokolo is Head of Global Patient Affairs at ViiV Healthcare and an honorary Consultant Physician in Sexual Health and HIV Medicine at Chelsea and Westminster Hospital in London where she continues to see patients in a combined general and menopause clinic. Date & time:...
Poz.com, January 21, 2021 On January 21, the Food and Drug Administration (FDA) in the USA approved the first complete injectable HIV treatment regimen that does not require daily pills. Cabenuva, from ViiV Healthcare, is administered only once a month. It is approved for people with an undetectable viral load on their current therapy who wish to switch to a long-acting regimen. Cabenuva consists...
July/August 2020 The Therapeutic Goods Administration (TGA) advises: Consumers and health professionals are advised that there is a shortage of oral contraceptive pills containing the combination ethinylestradiol and norethisterone. The affected products are: Brevinor – norethisterone 0.5 mg and ethinylestradiol 35 micrograms Norimin – norethisterone 0.5 mg and ethinylestradiol 35...
SHINE SA, September 2020 The contraceptive implant (Implanon NXT) is one of the most effective contraceptives available. Along with the hormonal and copper IUDs, it is classified as Long Acting Reversible Contraception (LARC) which are recommended as first-line options for all people choosing to use contraception. SHINE SA wish to alert clinicians to important updated information about Implanon...
Evofem Biosciences via PRNewswire, May 22nd 2020 Evofem Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is the first non-hormonal, on-demand...
NAPWHA, May 2019 This NAPWHA report is an analysis drawing together several years’ worth of data from the main pharmaceutical industry suppliers of compassionate access antiretroviral (ARV) therapy in Australia and combines this with, for the first time, data from the State and Territory jurisdictions to produce the most accurate estimate to-date of the number of Medicare ineligible PLHIV in...